Therma Bright (THRM) AI Stock Analysis

• Market Cap: $4.26M
• Dividend Yield: N/A
• Average Volume (3M): 71.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 57.50%
• EPS Growth: 16.20%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 56,807,144
• 10 Day Avg. Volume: 63,462
• 30 Day Avg. Volume: 71,055
• PEG Ratio: -10.03
• Price to Book (P/B): 238.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -32.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Therma Bright's overall score is primarily driven by its challenging financial performance and weak technical indicators. The valuation reflects ongoing losses, while positive corporate events provide some potential upside.

Therma Bright Business Overview & Revenue Model

Company Description

Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.

How the Company Makes Money

Therma Bright generates revenue through the sale and licensing of its proprietary medical devices and diagnostic tools. Key revenue streams include direct product sales to healthcare providers, distributors, and consumers, as well as licensing agreements with other companies in the healthcare sector. The company may also engage in strategic partnerships and collaborations to expand its market reach and enhance product offerings, thereby contributing to its earnings.

Therma Bright Financial Statement Overview

Summary

Therma Bright faces significant financial challenges, with ongoing profitability and liquidity issues despite revenue growth and a stable balance sheet.

Income Statement

Therma Bright has experienced fluctuating revenue growth, with a notable increase in TTM (Trailing-Twelve-Months). However, the company remains unprofitable with negative net profit margins, EBIT, and EBITDA margins consistently over the years, indicating ongoing operational challenges.

Balance Sheet

The company's balance sheet shows moderate leverage with a low debt-to-equity ratio. However, the return on equity is negative due to persistent losses. The equity ratio has improved, indicating better asset financing through equity rather than debt.

Cash Flow

Therma Bright's cash flow statement shows negative free cash flow and operating cash flow, highlighting liquidity issues. While there is some improvement in operating cash flow to net income ratio, the free cash flow to net income ratio remains weak.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	26.07K	23.90K	139.43K	3.88K	3.78K
Gross Profit	25.46K	23.90K	63.48K	3.88K	3.78K
EBITDA	-2.34M	-3.68M	-5.83M	-8.55M	-606.31K
Net Income	-2.45M	-3.77M	-5.88M	-8.61M	-626.68K
Balance Sheet
Total Assets	3.19M	2.21M	4.00M	2.24M	1.15M
Cash, Cash Equivalents and Short-Term Investments	1.10K	182.24K	3.08M	1.78M	1.06M
Total Debt	65.39K	90.39K	110.55K	40.00K	95.94K
Total Liabilities	1.87M	2.16M	1.25M	927.12K	924.32K
Stockholders Equity	1.32M	44.79K	2.75M	1.32M	223.97K
Cash Flow
Free Cash Flow	-1.01M	-2.44M	-3.80M	-3.16M	-104.94K
Operating Cash Flow	-1.01M	-2.17M	-3.80M	-2.86M	-104.94K
Investing Cash Flow	-138.26K	-691.08K	-204.93K	-300.00K	0.00
Financing Cash Flow	966.40K	-33.60K	5.31M	3.87M	1.14M

Therma Bright Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:THRM, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.10, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:THRM.

Therma Bright Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASG	61 Neutral	C$26.54M	―	-23.87%	―	18.97%	17.57%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
PINK	49 Neutral	C$24.24M	―	-163.62%	―	245.01%	-4.91%
TLT	48 Neutral	C$49.66M	―	-291.48%	―	-8.63%	7.04%
THRM	45 Neutral	$4.26M	―	-224.63%	―	57.50%	16.20%
VPT	44 Neutral	C$23.37M	―	207.08%	―	280.56%	-7.28%
PMEDF	―	$3.54M	―		―	―	―

Therma Bright Corporate Events

Therma Bright Announces Share Consolidation to Streamline Share Structure

Therma Bright Inc. announced a share consolidation effective July 8, 2025, where every eight pre-consolidation shares will be consolidated into one post-consolidation share. This move will reduce the number of shares from approximately 454 million to about 57 million, impacting the company’s stock options and warrants accordingly. The consolidation is expected to streamline the company’s share structure and potentially enhance its market positioning.

Therma Bright Announces Share Consolidation to Enhance Financial Flexibility

Therma Bright Inc. has announced a consolidation of its common shares, subject to TSX Venture Exchange approval, at a ratio of eight pre-Consolidation shares for one post-Consolidation share. This move is intended to provide the company with greater flexibility in structuring financings and business transactions, with no changes to its name or trading symbol expected.

Therma Bright Proposes Warrant Amendments and Debt Settlements

Therma Bright Inc. has announced its intention to amend the exercise price of 42,725,000 outstanding common share purchase warrants, pending approval from the TSX Venture Exchange. The amendment aims to adjust the exercise price to $0.05 per share until December 31, 2025, and $0.10 per share thereafter until expiration in 2027. Additionally, Therma Bright has negotiated debt settlements with creditors, proposing to settle $124,000 in debt by issuing 6,200,000 common shares at $0.02 per share, subject to TSXV acceptance. These strategic financial adjustments could impact the company’s market positioning and stakeholder interests.

Therma Bright Advances InStatin Development with New Strategic Advisor and Preclinical Success

Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes, a renowned respiratory clinician, as a strategic advisor, and has completed a successful preclinical pharmacokinetic study. Additionally, Dr. Amir Zeki received a grant from the NIH for a statin efficacy study in monkeys. InStatin is also strengthening its intellectual property position with the help of an experienced IP attorney. These developments suggest a strategic entry into the asthma treatment market, potentially expediting regulatory approval compared to the COPD market.

Therma Bright Advances InStatin Development with Strategic Appointments and Preclinical Success

Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes as a strategic advisor, completed a rodent pharmacokinetic study, and received a grant for a statin efficacy study in monkeys. These developments, along with efforts to strengthen their intellectual property, position InStatin to advance towards clinical trials and potentially address unmet needs in respiratory disease treatment.

Therma Bright Gains Market Traction with New Venowave Order

Therma Bright Inc. has secured an initial purchase order for 200 units of its Venowave VW5 product from a key distributor in the Durable Medical Equipment sector, indicating strong market confidence in its offerings. This development highlights the potential for significant follow-on orders and expansion opportunities, as the company continues to navigate the global trade environment and manage debt settlements through share issuance.